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Abstract
Background and Objectives: Left ventricular mass (LVM) is known to be related to overall and cardiovascular mortality in end
stage kidney disease (ESKD) patients. The aims of the present study are 1) to determine whether LVM is associated with mortality
and various cardiovascular events and 2) to identify determinants of LVM including biomarkers of inflammation and fibrosis.
Design, Setting, Participants, & Measurements: Analysis was performed with data of 327 ESKD patients, a subset from the
CONvective TRAnsport STudy (CONTRAST). Echocardiography was performed at baseline. Cox regression analysis was used
to assess the relation of LVM tertiles with clinical events. Multivariable linear regression models were used to identify factors
associated with LVM.
Results: Median age was 65 (IQR: 54–73) years, 203 (61%) were male and median LVM was 227 (IQR: 183–279) grams. The
risk of all-cause mortality (hazard ratio (HR) = 1.73, 95% CI: 1.11–2.99), cardiovascular death (HR= 3.66, 95% CI: 1.35–10.05)
and sudden death (HR= 13.06; 95% CI: 6.60–107) was increased in the highest tertile (.260grams) of LVM. In the
multivariable analysis positive relations with LVM were found for male gender (B = 38.8610.3), residual renal function
(B = 17.968.0), phosphate binder therapy (B = 16.968.5), and an inverse relation for a previous kidney transplantation
(B =241.167.6) and albumin (B =22.961.1). Interleukin-6 (Il-6), high-sensitivity C-reactive protein (hsCRP), hepcidin-25 and
connective tissue growth factor (CTGF) were not related to LVM.
Conclusion: We confirm the relation between a high LVM and outcome and expand the evidence for increased risk of
sudden death. No relationship was found between LVM and markers of inflammation and fibrosis.
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Introduction
Increased left ventricular mass (LVM) has been well described
as a frequent component of end stage kidney disease (ESKD) [1].
In fact, more than seventy percent of patients starting dialysis show
left ventricular hypertrophy (LVH) on echocardiography [2]. An
increase in left ventricular mass (LVM) is associated with
cardiovascular morbidity and mortality [3,4]. Although the
relation between LVM and overall mortality and cardiovascular
events has been well established in ESKD patients, the association
between LVM and certain types of cardiovascular morbidity (such
as coronary heart disease: CHD) and mortality (such as sudden
death) has not yet been thoroughly investigated.
Several inflammatory biomarkers associated with cardiovascular
pathology and morbidity have been described for patients with
chronic kidney disease (CKD). High sensitivity C-reactive protein
(hsCRP and interleukin-6 (Il-6) are both well accepted markers of
inflammation, related to increased risk of death and cardiovascular
disease [5]. HsCRP is an acute phase reactant, which has been
associated with an increased risk of major cardiovascular disease
[6]. HsCRP levels are higher in HD patients than in healthy
individuals [7] and have been shown to be independent predictors
of LVM indexed for body surface area (LVMi) in CKD patients
[8]. Il-6 is a short acting protein secreted by cells of the immune
system in response to inflammatory stimuli, and is suspected to be
a central regulator in the inflammatory process that leads to
atherosclerosis [9]. Several studies have reported the relation
between a high Il-6 and increased risk of developing CVD [10–
12]. In patient deceased from acute myocardial infarction, Il-6 has
been associated with mechanisms of cardiac hypertrophy [13].
Furthermore, Il-6 levels are increased in dialysis patients [7,14].
Connective tissue growth factor (CTGF) is a signalling protein
involved in the pathogenesis of renal and cardiac fibrosis [15]. In
animal studies CTGF has been described to contribute to
development of cardiac hypertrophy [16,17]. CKD patients have
a higher plasma CTGF level then healthy individuals, since CTGF
is eliminated predominantly by the kidney [18].
Hepcidin-25 is a peptide produced by the liver, which regulates
intestinal absorption of iron and its distribution through the body
[19]. The gene encoding for hepcidin-25 is regulated in response
to anemia, hypoxia and inflammation [20]. Furthermore,
hepcidin-25 is related to increased risk of cardiovascular events
in chronic hemodialysis patients [21].
Although several studies have described a relationship between
hsCRP and left ventricle geometry and function [8,22,23], the
relationship between LVM and the four described biomarkers has
not been examined in a large population of HD patients.
We hypothesize that a high LVM will be related to a higher risk
of mortality and cardiovascular events in our study, as is the case
in previously studied dialysis populations. Furthermore we expect
to find a positive relation between specific cardiovascular events
such as risk of CHD or sudden death and LVM. Regarding
hsCRP, Il-6, CTGF and hepcidin-25, since these markers are
related to pathophysiological mechanisms that could theoretically
promote increase of LVM, we assume to find a positive relation
between the magnitude of LVM and hsCRP, Il-6, CTGF and
hepcidin-25. Hence, the aims of this study are 1) to determine
whether LVM is associated with mortality and various cardiovas-
cular events in our population of ESKD patients and 2) to identify
determinants of LVM including biomarkers of inflammation,
systemic iron homeostasis and fibrosis in HD patients.
Materials and Methods
Patients
The present study included a subset of patients participating in
the CONvective TRAnsport STudy (CONTRAST): 327 hemo-
dialysis patients from 15 dialysis centres (14 Dutch centers and 1
Canadian center). CONTRAST has been designed to investigate
the effects of increased convective transport by online HDF as
compared with low-flux HD on all-cause mortality and cardio-
vascular morbidity and mortality (ISRCTN38365125) and
included a total of 714 patients [24].
The study was conducted in accordance with the Declaration of
Helsinki and approved by the medical ethics review boards of all
participating dialysis centres. Written informed consent was
obtained from all patients prior to enrolment. The names of the
medical ethics committees/review boards that have approved this
study are listed in the appendix S1 in File S1.
Data collection
Baseline patient and dialysis characteristics were used for this
analysis: information on demography, anthropometrics, medical
history, medication and standard laboratory values. A history of
cardiovascular disease was defined as a previous acute myocardial
infarction, coronary artery bypass graft, percutaneous translumi-
nal coronary angioplasty, angina pectoris, stroke, transient
ischemic attack, intermittent claudication, amputation, percuta-
neous transluminal angioplasty, peripheral bypass surgery and
renal percutaneous transluminal angioplasty.
Systolic and diastolic blood pressure was measured before and
after three consecutive dialysis sessions at baseline using a standard
electronic sphygmomanometer. The average of these measure-
ments was computed and used for analysis.
The primary outcome of CONTRAST was all cause mortality.
Cause of death was recorded and subdivided into cardiovascular
mortality (fatal myocardial infraction, fatal cerebrovascular
accident, fatal decompensatio cordis, a rupture of the abdominal
aorta or sudden death) and non-cardiovascular mortality. Sudden
death was defined as death within 1 hour of the onset of symptoms
as verified by a witness.
The main secondary endpoint was a composite of fatal and non-
fatal cardiovascular events. Cardiovascular events were defined as
death from cardiovascular causes, non-fatal myocardial infarction,
non-fatal stroke, therapeutic coronary procedure (percutaneous
transluminal coronary angioplasty and/or stenting), therapeutic
carotid procedure (endartrectomy and/or stenting), and vascular
intervention not related to vascular access (revascularisation,
percutaneous transluminal angioplasty and/or stenting) or ampu-
tation. Congestive heart failure was excluded as a cardiovascular
event, since the distinction with fluid overload is often difficult to
make in patients with end stage renal disease.
Follow-up of patients with respect to mortality and non-fatal
cardiovascular events was continued even after they stopped with
the randomized treatment because of a renal transplant (n = 71), a
switch to peritoneal dialysis (n = 5), a move to another non-
CONTRAST hospital (n = 11) or a stop of participation for other
reasons (n = 58).
An independent Endpoint Adjudication Committee reviewed
source documentation for all primary outcome events (deaths), as
well as non-fatal cardiovascular events and infections.
LVM and Clinical Events
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Laboratory measurements
Standard laboratory samples were analysed in the local
laboratories of the participating hospitals by standard laboratory
techniques.
Furthermore, in centres where storage of blood samples was
logistically feasible, additional blood samples were drawn for the
analysis of hsCRP, Il-6, CTGF and hepcidin prior to dialysis.
Samples were placed on ice, and centrifuged within 30 min, at
1500 g for 10 minutes, and were stored at 280uC until assayed. A
total of 248 patients, out of the 327 who underwent echocardi-
ography, were treated in such centers and therefore had additional
measurements of hsCRP, Il-6, CTGF and hepcidin.
High sensitivity CRP, hepcidin-25, CTGF and IL-6 levels were
measured centrally. Measurements of the bioactive hepcidin-25
were performed with time of flight mass spectrometry which has
been described previously [25]. High sensitivity CRP (mg/L) was
measured with a particle-enhanced immunoturbidimetric assay on
a Roche-Hitachi analyzer as described elsewhere [21]. IL-6 (pg/
mL) was measured with an ELISA (Sanquin, Amsterdam, The
Netherlands), details have been described earlier [26]. CTGF
levels in plasma were determined by sandwich ELISA, using two
specific antibodies (FibroGen Inc., San Francisco, CA, USA)
directed against two distinct isotopes in the amino-terminal
fragment of CTGF, detecting both full length CTGF and the N-
fragment, as shown earlier [18].
Echocardiographic measurements
In 15 centres, patients were requested to undergo 2-dimensional
echocardiography next to the standard CONTRAST baseline
data collection.
Transthoracic echocardiography studies were performed on a
mid-week non-dialysis day by an echocardiographer at the
participating local hospital. From the parasternal long axis position
the left ventricular end-diastolic diameter (LVEDD), end-systolic
diameter (LVESD) as well as the posterior and septal wall thickness
were determined. The ultrasound investigations were then assessed
by an independent experienced echocardiographer at the core
laboratory (VUmedical Center, Amsterdam, the Netherlands), who
was blinded for other patient data. LVM was calculated using the
formula of Devereux and Reickek [27], modified in accordance with
the recommendations of the American Society of Echocardiogra-
phy [28]. LVH was defined as an LVM/height2.7 .44g/m2.7 for
women and .48 g/m2.7 for men [3].
Table 1. Demographic, anthropometric, biochemical,
hemodynamic and dialysis characteristics of the study
population.
Total Cohort Echo cor cohort
n =714 n=327
Demographic data
Male gender 445 (62%) 200 (61%)
Race, Caucasian 304 (85%) 263 (80%)
Age, years 64.1613.7 63.0613.3
Smoking 133 (19%) 66 (20%)
Anthropometrics
Length (cm) 168610 168611
Weight (kg) 72.4614.4 72.1614.3
BMI (kg/m2) 25.4614.4 25.564.9
Body Surface Area (m2) 1.85 (0.28)* 1.85 (0.30)*
Dialysis Properties
Dialysis vintage (years) 1.8 (1.0–4.0)* 2.0 (1.0–4.0)*
Duration of dialysis (minutes) 226623 225623
Blood flow (mL/minute) 300 (300–348)* 300 (300–350)*
spKt/Vurea 1.4060.22 1.3960.20
AV fistula 279 (78%) 260 (80%)
Patients with residual kidney
function
186 (52%) 171 (52%)
Comorbidities
Cardiovascular disease 313 (44%) 146 (45%)
Diabetes 170 (24%) 83 (25%)
Previous kidney transplant 78 (11%) 30 (9%)
Laboratory parameters
Hemoglobin (g/dL) 11.860.40 11.861.3
Phosphate (mmol/L) 1.6460.49 1.6760.50
Calcium (mmol/L) 2.3160.18 2.3060.18
Albumin (g/L) 40.463.8 41.2 (37.9–43.5)*
Creatinine (mmol/L), pre-dialysis 8616255 8836252
hsCRP (mg/L) - 4.0 (1.6–11.9)*
Il-6 (pg/mL) - 2.0 (1.2–3.8)*
CTGF (nmol/L) - 3.6 (2.8–4.3)*
Hepcidin -25 (nM) - 14.2 (6.3–22.4)*
Ferritin (ng/mL) - 377 (211–597)*
TSAT (%) - 22 (15–29)*
Medication
Erythropietin therapy 314 (88%) 295 (91%)
Diuretic therapy 250 (35%) 129 (39%)
Beta-blocker therapy 184 (51%) 174 (53%)
RAS inhibitor therapy 179 (50%) 162 (50%)
Lipid lowering therapy 196 (55%) 152 (47%)
Vitamin D administration 227 (63%) 222 (68%)
Phosphate binding therapy 445 (62%) 194 (59%)
Platelet aggregation therapy or
coumarines
111 (34%) 122 (36%)
Iron supplements 476 (67%) 213 (65%)
Hemodynamic measurements
Systolic blood pressure (mm Hg) 147621 142619
Table 1. Cont.
Total Cohort Echo cor cohort
n =714 n=327
Diastolic blood pressure (mm Hg) 75612 74610
LVEDD (mm) - 10 (9–11)*
LVESD (mm) - 32 (27–38)*
EFLV (%) - 65 (55–72)*
LVM (g) - 227 (183–279)*
LVH - 230 (71%)
*:median and IQR (P25–P75).
AV: arterio-venous;BMI: mody mass index; CTGF: connective tissue growth
factor; EFLV: ejection fraction of left ventricle; hsCRP: high sensitivity C-reactive
protein; Il-6: interleukin 6; LVEDD: left ventricular end diastolic diameter; LVESD:
left ventricular end systolic diameter; LVH: left ventricular hypertrophy; LVM: left
ventricular mass; RAS: renin-angiotensin system; TSAT: transferrin saturation.
doi:10.1371/journal.pone.0084587.t001
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Data analysis
Data were reported as proportions or as means with standard
deviation (SD) or medians with inter-quartile ranges (IQR) when
appropriate.
The average percentage of missing values per variable was
7.7%. No data were missing regarding clinical events. Multiple
imputation was performed on all variables, where ,40% of data
were missing. One variable was not imputed due to a higher
percentage of missing values, namely blood flow. Imputation was
performed to prevent bias in reported estimates and to improve
statistical power [29].
To study the independent relation of each variable with LVM,
linear regression analysis was used. Patient and dialysis related
variables that showed a univariable relation with LVM using a cut-
off p-value ,0,20 were entered in a multivariate model in
consequent groups: demographic data, patient history, dialysis
properties, therapeutic parameters and haemodynamic measure-
ments. In addition, height and weight were added into the model
upfront.
In a separate analysis, the variables hsCRP, Il-6, hepcidin-25
and CTGF were added to the constructed multivariate model one
at a time. The old and new models were compared based on
direction of the estimate and the significance of the regression
coefficient of the added marker.
The relations between LVM and all-cause mortality, as well as
cardiovascular events, cardiovascular death, sudden death and
CHD were evaluated by Cox proportional hazards models,
involving the time to the first relevant endpoint in any individual
patient. For this analysis LVM was both analysed as a linear
variable and divided into categories (tertiles). The number of
events (in particular sudden death and CHD events) was small,
and thus adjusting for all relevant possible confounders would lead
to an overfitted model. Propensity scores as opposed to individual
variables were used to adjust the models thus omitting the problem
of an overfitted model. The propensity score [30] model estimated
each individuals probability of having an LVM above the median
of the studied population. Propensity score was built using a
logistic model including all variables associated with LVM with
p,0.20. Moreover, height, post-dialysis baseline weight and
dialysis modality (intervention) were added into the propensity
score model upfront.
Results were considered statistically significant when p,0.05
(two-sided). All calculations were made by use of a standard
statistical package (SPSS for Windows Version 18.0.1; SPSS Inc.
Headquarters, Chicago, Illinois, US).
Results
327 patients participating in CONTRAST underwent echocar-
diography. Out of this group, in 248 patients blood was collected
for a measurement of markers of inflammation and fibrosis.
Median age was 65 (IQR: 54–73) years, 203 were male (61%) and
the median dialysis vintage was 2.0 (IQR: 1.0–4.0) years. Median
LVM was 227 (IQR: 183–279) grams. A total of 230 patients
(71%) had LVH. The baseline characteristics of the whole
CONTRAST cohort and of the echocardiography population
are shown in table 1. The mean follow-up time was 2.0 (minimum
0.1, maximum 6.5) years. Within the group of patients with an
LVM measurement 130 (39.8%) patients died from any cause and
116 (35.5%) had a cardiovascular event, out of which 43 (13.1%)
were fatal. CHD (angina pectoris or acute myocardial infarction)
occurred in 53 (16.2%) patients, of whom 3 (0.9%) died. Sudden
death occurred in 24 (7.3%) patients.
Relation to LVM and outcome
Table 2 shows proportional hazard ratios for all-cause mortality,
cardiovascular death, sudden death, combined fatal and non-fatal
cardiovascular events and CHD events; both crude and adjusted
using propensity scores. Risk of all-cause mortality, cardiovascular
death and sudden death was increased in the highest tertile
(.260grams) of LVM; while no difference in risk was found for
overall cardiovascular events and CHD events in the LVM tertiles.
Figure 1 shows survival curves for the clinical events described
above stratified by LVM tertiles.
As shown in Table S1a and S1b in File S1, when LVM was
indexed for BSA or height2.7, relations with clinical events were
similar.
Table 2. Hazard ratio of clinical events by LVM in grams divided into tertiles.
T1: ,201 T2: 201,LVM,260 95% CI T3: .260 95% CI
Crude
Mortality 1 1.61* 1.01–2.55 2.17* 1.39–3.38
Cardiovascular death 1 2.24 0.90–5.55 3.76* 1.61–8.82
Sudden death 1 8.93* 1.12–71.4 17.8* 2.35–135.0
Cardiovascular events 1 1.47 0.92–2.44 1.66* 1.06–2.67
CHD events 1 1.04 0.51–2.13 1.13 0.56–2.31
Adjusteda
Mortality 1 1.50 0.92–2.10 1.73* 1.11–2.99
Cardiovascular death 1 1.80 0.64–5.07 3.69* 1.35–10.05
Sudden death 1 6.29 0.72–52.70 13.06* 6.60–107.16
Cardiovascular events 1 1.27 0.74–2.18 1.49 0.85–2.60
CHD events 1 1.22 0.71–2.09 1.51 0.87–2.64
*p,0.05.
aAdjusted with a propensity score containing determinants of LVM (male gender, residual renal function, history of kidney transplantation, albumin, use of RAS-
inhibitors, use of phosphate binders, systolic blood pressure) and history of cardiovascular disease, diabetes, height, post-dialysis weight and dialysis modality
(intervention).
doi:10.1371/journal.pone.0084587.t002
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Determinants of LVM
The univariable and multivariable analysis results of LVM are
shown in Table 3. In the multivariate analysis significant positive
relations with LVM were found for male gender, presence of
residual renal function and phosphate binder therapy. There were
inverse relations for a history of kidney transplantation and
albumin. The complete-case multivariate regression analysis
showed similar results as demonstrated in Table S2 in File S1.
Table 4 shows that hsCRP, Il-6, hepcidin-25 and CTGF were
not related to LVM.
Figure 1. Survival curves for (A) time to death from any cause, (B) cardiovascular death, (C) sudden death, (D) cardiovascular events
(both fatal and non-fatal), (E) coronary heart disease events (both fatal and non-fatal, all stratified by LVM tertiles and adjusted
using propensity scores.
doi:10.1371/journal.pone.0084587.g001
LVM and Clinical Events
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Discussion
The present study confirmed the relation between a high LVM
and outcome [2,4,31,32]. Furthermore we expanded the evidence
for a strongly increased risk of sudden death in patients with a high
LVM. After confirming that LVM was a strong predictor of
cardiovascular and overall mortality we wanted to study what
factors determine the magnitude of LVM, and in particular if these
determinants were potentially modifiable. In our analysis, factors
related to LVM were: male gender, history of kidney transplan-
tation, residual kidney function (RKF), albumin and use of
phosphate binders. Thus we did not find determinants of LVM
that could easily be altered in daily clinical practice. Lastly, we
explored whether novel markers of inflammation, fibrosis and iron
homeostasis (hsCRP, Il-6, CTGF and hepcidin-25), which in
theory could lead to a higher LVM, were related to LVM in a
large population of hemodialysis patients. Apparently, although
hsCRP, Il-6, CTGF, hepcidin-25 have previously been found to be
associated with cardiovascular damage, no relation exists between
these biomarkers and the magnitude of LVM in ESKD patients.
Table 3. Determinants of LVM in dialysis patients: univariable and multivariable regression analysis.
Univariable model Multivariable model
Determinant B 95% CI B 95% CI
Demographic data
Male gender 56.47 39.03 to 73.90 38.80 18.64 to 58.96
Race, Caucasian 12.92 29.75 to 35.60
Age (years) 0.75 0.08 to 1.42
Smoking 22.20 20.47 to 44.87
Dialysis Properties
Duration of dialysis (hours) 35.14 10.95 to 59.33
spKt/Vurea 2102.7 2145.7 to 259.75
AV fistula 17.59 24.66 to 38.83
Comorbidities
Cardiovascular disease 16.54 21.50 to 34.58
Diabetes 1.94 218.45 to 22.37
Previous kidney transplant 249.76 280.38 to 219.01 241.12 255.94 to 226.31
Dialysis vintage (years) 25.45 28.61 to 22.30
Residual kidney function 29.28 211.52 to 47.04 17.88 2.16 to 33.61
Laboratory parameters
Hemoglobin (g/dL) 21.00 212.53 to 10.53
Phosphate (mmol/L) 0.89 217.17 to 18.94
Calcium (mmol/L) 13.37 232.36 to 63.99
Calcium*Phosphate 1.28 26.48 to 9.03
Albumin (g/L) 21.99 24.17 to 0.20 22.94 25.08 to 20.81
Creatinin (mmol/L) 20.02 20.05 to 0.02
Therapeutic parameters
Erythropietin 29.68 238.78 to 19.38
Diuretic 0.97 218.99 to 20.94
Beta-blocker 16.26 21.70 to 34.21
Alpha-blocker 21.44 213.64 to 56.51
RAS inhibitor 21.67 3.82 to 39.51 14.08 22.46 to 30.62
Lipid lowering therapy 0.95 217.06 to 18.95
Vitamin D administration 5.15 214.16 to 22.45
Phosphate binder 17.82 20.420 to 36.05 16.87 0.14 to 33.56
Platelet aggregation inhibitor 10.35 28.44 to 29.13
Coumarine derivates 22.50 214.09 to 59.08
Iron supplements 22.56 3.81 to 41.32
Hemodynamic measurements
Systolic blood pressure (mm Hg) 0.54 0.08 to 1.00 0.37 20.77 to 0.82
The B reflects the change of total LVM (in grams) related with one unit increment of the determinant.
R2 of the multivariable model = 0.22.
doi:10.1371/journal.pone.0084587.t003
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LVM and clinical events
A summary of previous papers in which the relation between
left ventricular geometry and clinical events was studied in dialysis
patients is shown in Table 5. Foley et al studied the relation
between LVM and mortality risks in 433 ESKD patients and
found a significant linear association between LVM and overall
mortality as well as cardiovascular mortality in particular [2].
Zoccali et al studied the prognostic impact of LVM indexed for
body surface are or height2.7 in 254 dialysis patients and found
that both types of LVMi were related to both overall mortality and
cardiovascular mortality [31].
We are among the first to describe the relationship between
LVM and sudden death specifically in ESKD patients. In fact,
ESKD patients in the highest tertile of LVM had an almost 14-fold
higher risk of sudden death when compared to the lowest LVM
tertile, while their risk of dying from a cardiac cause in general was
‘only’ increased by a factor 3.5. The underlying mechanism may
be through a decrease in myocardial capillary density, diastolic
and systolic dysfunction, disturbances in interventricular conduc-
tion, chamber dilatation and eventually more compensatory
hypertrophy. These processes lead to an increased risk of
triggering a fatal arrhythmia [1,33]. Autopsy studies in ESKD
patients point to the presence of diffuse inter-myocardiocyte
fibrosis specific for this group, which may indicate an electrical
instability predisposing to sudden death [34]. The percentage of
sudden deaths (56%) from all cardiac deaths in our population was
similar to those of earlier studies [33].
For a combination of fatal- and non-fatal cardiovascular events
no relation with LVM size was found. To our knowledge, no such
relation has been described in earlier literature; although Zoccali
et al found a significant relation between LVM indexed for
height2.7 and fatal- and non-fatal cardiovascular events combined
[31]. Since there were only 3 lethal CHD events in our study, this
association could not be explored in our population.
Determinants of LVM
Factors related to LVM were: male gender, history of kidney
transplantation, residual kidney function (RKF), albumin and use
of phosphate binders.
It was a surprising finding that a history of CVD and blood
pressure (BP) were not found to be associated with LVM.
Regarding the lack of relation between LVM and CVD this
could be attributed to the fact that our definition of CVD
encompassed several periphery vasculature diseases/interventions,
which do not necessarily lead to an enlargement of LVM. Also,
many ESKD patients have a high LVM without a history of CVD
[2]. While BP is very variable over time in dialysis patients (mostly
due to rigorous changes in extracellular volume during and in-
between dialysis treatments), our BP results are an average of three
pre- and three post-dialysis BP measurements. Hence our BP
Table 4. Hepcidin, hsCRP, Il-6 and CTGF as determinants of LVM.
Univariable model Adding to ‘basic’ multivariable model
Determinant B 95% CI B 95% CI DR2
Hepcidin-25 (nM) 20.04 20.46 to 0.38 0.04 20.38 to 0.45 20.003
hsCRP (mg/L) 0.22 20.46 to 0.90 0.07 20.43 to 0.57 20.003
Il-6 (pg/mL) 0.03 20.17 to 0.22 0.06 20.13 to 0.23 20.002
CTGF (nmol/L) 0.05 23.92 to 4.01 0.67 23.45 to 4.78 20.001
The B reflects the change of total LVM (in grams) related with one unit increment of the determinant.
doi:10.1371/journal.pone.0084587.t004
Table 5. Summary of previous studies in which the relation between LV geometry and clinical events was examined in dialysis
patients.
Author patient nr LV measurement event Risk measure Conclusion
Silverberg et al 133 LVMi (g/m2) mortality RR: 2.9 (p = 0.013) LVH is an important determinant of survival
1989 (33) CV mortality RR: 2.7 (0.08) in incident dialysis patients
Foley et al 433 LVMi (g/m2) mortality RR: 1.003 (p = 0.11) LVH is highly prevalent in th dialysis
1995 (2) late (.2 yr) mortality RR: 1.009 (p,0.001) population and is a risk factor for mortality
London et al 153 more than 10% decrease mortality RR: 0.78 (p = 0.001) partial regression of LVM has a favorable
2001 (4) in LVMi (g/height2.7) CV mortality RR: 0.72 (p = 0.002) effect on mortlity and CV-mortality
Zoccali et al 254 LVMi (g/m2) mortality HR: 1.01 (p,0.001)/1.03 (p,0.001) LVM indexed for height2.7 provides a more
2001 (32) LVMi (g/height2.7) CV mortality HR: 1.01 (p,0.001)/1.03 (p,0.001) powerful predictor for death and CV events
CV event HR: 1.00 (ns)/1.02 (p = 0.004) compared to LVM indexed for BSA
Zoccali et al 161 in top 75% progression mortality HR: 3.07 (p = 0.008) Changes in LVMi have an independent
2004 (3) in LVMi (g/height2.7) CV event HR: 3.02 (p = 0.02) prognostic value for death and CV events
CV events are defined as a combination of both fatal and non-fatal cardiovascular events.
BSA: body surface area; CV: cardiovascular; HR: hazard ratio; LV: left ventricular; LVH: left ventricular hypertrophy; LVM: left ventricular mass; LVMi: left ventricular mass
index; nr: number; RR: relative risk.
doi:10.1371/journal.pone.0084587.t005
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measurements could be a poor representative of the total BP
burden of a patient (which is truly related to LVM).
The relation between LVM and a history of kidney transplan-
tation [35,36] and albumin [37] is in accordance with earlier
literature.
The positive relation between LVM and RKF may be explained
by a ‘survivor bias’: patients that still have RKF have been on
dialysis for a shorter period of time. As time passes, the patients
with a high LVM are more likely to die, the patient with a lower
LVM remain and lose their RKF. In our population, the dialysis
vintage differs significantly between patient with RKF (1.9261.58
years) and without RKF (4.0063.4 years).
Previous studies on predictors of LVM and LVMi in HD
patients identified phosphate and the calcium-phosphate product
as patient characteristics associated with LVH [38–40]. In our
analysis however, these laboratory values were not significantly
related to LVM, while there was a positive association between
LVM and use of phosphate binders. The serum calcium and
phosphate are well controlled in our dialysis population, and
phosphate binders were prescribed to 74% of the patients (mainly
sevelamer, a non-calcium containing phosphate binder: 54%).
Hyperphosphatemia can lead to vascular calcification and
myocardial fibrosis, resulting in increased cardiovascular risk
[41]. Thus, it is plausible that in our population the prescription of
phosphate binders is a reflection of higher phosphate intake at
present and/or hyperphosphatemia in the past, resulting in higher
LVM.
Relation between LVM and hsCRP, Il-6, CTGF, hepcidin
We are among the first to investigate the association between
LVM and the biomarkers hsCRP, Il-6, CTGF and hepcidin in a
population of ESKD patients, which is also large enough to
perform appropriate corrections for clinically relevant variables
without creating an overfitted model. Although there is a
theoretical incentive, as described in the Introduction, to
hypothesize that these biomarkers may contribute to LVM, we
do not find such a relation in our population. Apparently,
although hsCRP, Il-6, CTGF, hepcidin-25 have previously been
found to be associated with cardiovascular damage, no relation
exists between these biomarkers and the magnitude of LVM in
ESKD patients.
In earlier papers concerning LVM and prognosis, LVM was
indexed for body surface are, or divided by height2.7. It was shown
that these indexations, especially LVM/height2.7 are better
predictors of clinical events than LVM. [3,4]) A downside of
ratios is that observed relation may be due to the nominator, the
denominator or both. Therefore in the present analyses we chose
to use LVM for our analyses only with correction for height and
weight in the propensity scores for optimal statistical adjustment.
As shown in Tables S1a and S1b in File S1, when LVM was
adjusted for height and weight, the relation with clinical events was
similar to that of LVM indexed for BSA or height2.7.
Strengths and limitations
This study had several limitations. First, 7.7% of data was
missing and biomarkers were measured in only 75.5% of the
patients. However, since multiple imputation was performed for
missing variables included in the multivariable analysis, this
prevents the drawing of wrong conclusions due to the fact that
data may be missing in specific patients for a reason, and not by
chance and by increasing the power of our analyses [29].
Furthermore, our sensitivity analyses of complete cases showed
no marked differences with the regression performed on the
imputed data. Second, the number of CHD events and sudden
deaths was small, thus limiting the precision of our estimates.
Third, since cross-sectional data was used to determine variables
related to LVM, causality of relations cannot be established.
Fourth, measurements of LVM by echocardiography is less precise
and reliable than measurement by cardiac magnetic resonance
imaging (CMRI) [1]. However, while CMRI is recognized as the
‘‘gold standard’’ for ventricular geometry measurements, it is less
often applied in clinical practice since it is more expensive, not
widely available and has contra-indications such as claustrophobia
and use of cardiac implantable devices [1]. Thus it was not feasible
to perform CMRI measurements in our relatively large cohort of
dialysis patients. This may have led to misclassification, which
generally leads to an underestimation of the magnitude of the
relations under study.
The strengths of this study are the large sample size, the concise
and prospective data collection, the independent review of source
documentation for all primary and secondary outcomes and the
double independent analysis of the echocardiography recordings
blinded for patient characteristics.
Conclusion
In this study we confirmed the relation between LVM and all-
cause mortality. Furthermore we demonstrated a markedly
increased risk of sudden death in patients with a high LVM.
No relationship was found for markers of inflammation (except
for a negative association with albumin) and fibrosis.
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